# Restore weight-based dosing and vial sharing for immunotherapy in the label

Source: https://onco.cc/ideas/idea-reg-weight-based-io-dosing-label/  
OnCo record `idea-reg-weight-based-io-dosing-label` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immunotherapy is given as one flat dose regardless of body size, which means smaller patients get more than they need. Dosing by weight would save a fifth of the drug at no cost to patients.

## Summary

Pembrolizumab and nivolumab were developed with weight-based dosing but labelled at flat doses (200 mg, 240 or 480 mg) that exceed the weight-based equivalent for most patients; pharmacokinetic modelling and several observational studies suggest no loss of efficacy from weight-based or capped dosing, and Dutch and other groups estimate savings of 20-30%. The proposal is a regulator-endorsed label update permitting weight-based dosing with dose banding and multi-dose vial sharing, supported by a pragmatic non-inferiority trial where regulators require one.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Weight-based, banded dosing reduces checkpoint inhibitor drug spend per patient by at least 20% with overall survival non-inferior to flat dosing (hazard ratio upper bound below 1.1).
- Rationale: Exposure-response for PD-1 antibodies is flat across the approved range, so the flat doses were chosen for convenience and, arguably, revenue; the drug is the same either way.
- Proposed test: Pragmatic registry-based randomised trial in one health system comparing weight-based banded dosing with flat dosing across indications, with survival and cost endpoints; petition regulators for label change on the result.
- Maturity: early-clinical
- Actor: clinic

## Sources

- Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017): https://doi.org/10.1038/nrclinonc.2017.31

## Connected records

- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- bottlenecks: [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)
- key papers: [CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy](https://onco.cc/key-papers/paper-checkmate-017-nejm-2015/), [KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation](https://onco.cc/key-papers/paper-keynote-189-nejm-2018/), [KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery](https://onco.cc/key-papers/paper-keynote-564-nejm-2021/), [The high price of anticancer drugs: origins, implications, barriers, solutions](https://onco.cc/key-papers/paper-prasad-nat-rev-clin-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-weight-based-io-dosing-label.json